Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Indian Govt Wants Drug Outlets In Every District

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - India's newly created department of pharmaceuticals has circulated a concept note among industry associations to solicit views on opening new drug distribution outlets in every district of the country

You may also be interested in...



India’s Expanding Middle Class To Drive Pharma Industry Annual Growth to 20 Percent By 2015

NEW DELHI - India's pharmaceutical industry is forecast to grow by nearly 20 percent annually by 2015, spurred by rising incomes and better health awareness, according to a study commissioned by Indian industry lobby group the Confederation of Indian Industry

GSK To Take Second Shot At The Rural Indian Market; Considering Customized Strategy

MUMBAI - India's largest multinational drug maker GlaxoSmithKline is planning a big entry into the country's rural pharmaceutical market. An exhaustive plan is being hammered out to understand the dynamics of the rural medicine market so that GSK can position itself correctly in the intensely price-sensitive market segment

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069621

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel